Advances in Gene Editing Technologies in Healthcare

Description

Next-generation genome editing tools and improved delivery are bolstering gene editing therapeutics and diagnostics.

Advancements in gene editing technology are boosting its adoption in various fields, including healthcare, diagnostics, agriculture, and industrial biotechnology. CRISPR, ZFNs, and TALENs are examples of technologies that have revolutionized the gene editing field. Moreover, with constant research efforts, new technologies such as base editing, prime editing, twin prime editing, and PASTE have emerged.

The adoption of gene editing technologies is focused on therapeutics and diagnostics, with CRISPR being the most widely used technology due to the numerous advantages it offers.

Immuno-oncology, blood disorders, and neuro-disorders are just a few of the diseases that gene editing technology targets. In addition, cardiovascular and viral diseases are intriguing areas that gene editing technology has the potential to treat.

A growth driver is the rising need for precise and targeted treatment for currently incurable diseases. Most gene editing companies use CRISPR technology for therapeutic and diagnostic development, mainly because CRISPR has the highest IP and is the most researched technology.

Companies are actively working to overcome the challenges associated with CRISPR technology, which has resulted in the development of novel delivery technologies, new miniaturized Cas molecules, and nuclease expression control. All these advancements accelerate the adoption of gene editing technologies. Increased venture capital and government funding are other factors driving the growth of these technologies.

Key Questions This Study Answers:

What is gene editing technology?

What are the growth drivers and restraints for gene editing technologies?

What are the emerging trends in gene editing-based therapeutics and diagnostics?

What does the tech innovation landscape look like?

What are the recent R&D activities and collaborations?

What are the growth opportunities for companies developing gene editing-based products?

Product Code: DA7F

Strategic Imperatives

Why Is It Increasingly Difficult To Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Gene Editing Technology Industry
Growth Opportunities Fuel The Growth Pipeline Engine™

Scope and Segmentation

Research Context
Research Coverage and Key Questions the Study Will Answer
Research Methodology
Development of Gene Editing Tools
Technology Assessment of Gene Editing Tools
Research Hubs for Gene Editing Technology
Uses of Gene Editing Technology in the Clinic-Therapeutics and Diagnostics

Growth Opportunity Analysis

Growth Drivers
Growth Driver Analysis
Growth Restraints
Growth Restraint Analysis
Emerging Trends in the Adoption of Genome Editing in the Clinic

R&D Focus

Technology Developments around CRISPR-Cas
Technology Developments around CRISPR-Cas to Improve Delivery
Technology Developments around CRISPR-Cas to Improve Precision
Next-generation Gene Editing Technology
Next-generation Gene Editing Technology (continued)
Next-generation Gene Editing Technology (continued)
Next-generation Gene Editing Technology (continued)
Emerging Participants Working on Next-generation CRISPR Technology
Emerging Technology Developers Leveraging CRISPR

Technology Innovation Ecosystem: Gene Editing Therapeutics and Diagnostics in Clinical Development

CRISPR/Cas: Applications across Indications
CRISPR/Cas: Applications across Indications (continued)
Major Participants Developing CRISPR-based Therapeutics
Major Participants Developing CRISPR-based Therapeutics (continued)
Development of CRISPR-based Gene Editing as Targeted Antibacterials
Development of CRISPR-based Gene Editing as Targeted Antivirals
Non-CRISPR-based Therapeutics
Major Participants Developing Non-CRISPR-based Therapeutics
Development of Gene Editing Tools in Diagnostics
CRISPR-Cas System-based Diagnostic Tools
CRISPR-Cas System-based Diagnostic Tools (continued)

Developments in In Vivo and Ex Vivo Delivery

Gene Editing Strategies: Developments in In Vivo and Ex Vivo Gene Editing Tools
Challenges and Limitations of Gene Editing Delivery Systems
Developments in Gene Editing Delivery
Current Approaches for Gene Editing Delivery
Current Approaches for Gene Editing Delivery (continued)
Developments in Viral Vectors for Gene Editing Delivery
Developments in Viral Vectors for Gene Editing Delivery (continued)
Developments in Nonviral Vectors for Gene Editing Delivery Carriers - Lipid-based Formulations
Developments in Nonviral Vectors for Gene Editing Delivery Carriers - Lipid-based Formulations (continued)
Cell/Cell Component-derived Carriers
Cell/Cell Component-derived Carriers (continued)
Polymer-based Formulations
Peptide-based Formulations
Development of Other Nanoscale Gene Editing Delivery Carriers
Development of Other Nanoscale Gene Editing Delivery Carriers (continued)
Nanoparticles
Nanoparticles (continued)
Development of Physical Methods of Delivery of Gene Editing Therapeutics
Development of Physical Methods of Delivery of Gene Editing Therapeutics (continued)

Key Stakeholder Ecosystem

A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies
A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)
A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)
A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)
A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)
A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)
A Growing Number of Collaborations are Transforming the Growth of Gene Editing Technologies (continued)
Technology Licensing
Technology Licensing(continued)
Acquisitions
Highlights of Gene Edited Therapeutics and Diagnostic Development Collaborations
Significant VC Funding Boosts the Development of Gene Editing Companies (2019-2022)
Significant VC Funding Boosts the Development of Gene Editing Companies (2019-2022) (continued)
Funding Analysis of Gene Editing Companies
Funding Analysis of Gene Editing Companies (continued)
Key Takeaways

Growth Opportunity Universe

Growth Opportunity 1: Advanced Delivery and Formulation Strategies for the Safe and Effective Delivery of Gene Editing Tools
Growth Opportunity 1: Advanced Delivery and Formulation Strategies for the Safe and Effective Delivery of Gene Editing Tools (continued)
Growth Opportunity 2: Emerging Applications of Gene Editing Technologies Open Profitable Growth Opportunities
Growth Opportunity 2: Emerging Applications of Gene Editing Technologies Open Profitable Growth Opportunities (continued)
Growth Opportunity 3: Advancements in Technologies to Make Them More Precise, Efficient, and Safe
Growth Opportunity 3: Advancements in Technologies to Make Them More Precise, Efficient, and Safe (continued)

Appendix

Future Outlook of Gene Editing Applications beyond Healthcare
Future Outlook of Gene Editing Applications beyond Healthcare (continued)
Different Gene Editing Tools under Clinical Study through the In Vivo and Ex Vivo Approaches
Different Gene Editing Tools under Clinical Study through the In Vivo and Ex Vivo Approaches (continued)
Existing Gene Editing Delivery Vectors
Existing Gene Editing Delivery Vectors (continued)
Technology Readiness Levels (TRL): Explanation

Next Steps

Your Next Steps
Why Frost, Why Now?
Legal Disclaimer